Development of highly effective anti-mesothelin hYP218 Chimeric Antigen Receptor T cells with increased tumor infiltration and persistence for treating solid tumorsAnti-mesothelin hYP218 Chimeric…

Overview of attention for article published in Molecular Cancer Therapeutics, May 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (82nd percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter: 6 X users
patent: 1 patent

wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 20 Dimensions

Readers on

mendeley: 21 Mendeley

Summary X Patents Wikipedia Dimensions citations

So far, Altmetric has seen 9 X posts from 6 X users, with an upper bound of 22,044 followers.

RT @MitchellHo: Happy to share preclinical data of anti-mesothelin hYP218 CAR-T. This was a joint project led by Dr. Raffit Hassan, Dr. Ira…

20 Aug 2022

Reply Repost Favourite

RT @MitchellHo: Happy to share preclinical data of anti-mesothelin hYP218 CAR-T. This was a joint project led by Dr. Raffit Hassan, Dr. Ira…

04 Aug 2022

Reply Repost Favourite

Happy to share preclinical data of anti-mesothelin hYP218 CAR-T. This was a joint project led by Dr. Raffit Hassan, Dr. Ira Pastan and our lab. hYP218 is a humanized rabbit monoclonal antibody targeting a membrane-proximal epitope of mesothelin. @NCIResear

04 Aug 2022

Reply Repost Favourite

ICYMI: Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors. https://t.co/Keh0JKWc71 https://t.co/WFdzMLEVCn

26 Jul 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 5 additional X posts.